Welcome to our dedicated page for Canopy Growth news (Ticker: CGC), a resource for investors and traders seeking the latest updates and insights on Canopy Growth stock.
Canopy Growth Corporation (CGC) is a global leader in cannabis production and consumer goods innovation. This news hub provides investors and industry observers with official press releases, financial updates, and strategic developments from one of the sector's most diversified companies.
Access real-time updates on CGC's medicinal cannabis research, recreational product launches, and international market expansions. Our curated collection includes earnings reports, partnership announcements, and regulatory compliance milestones across Canada, Europe, and U.S. markets through Canopy USA.
Key focus areas include vaporizer technology advancements, brand portfolio growth, and cultivation process innovations. Users will find detailed information on THC and CBD product developments, sustainability initiatives, and strategic moves in emerging cannabis markets.
Bookmark this page for direct access to verified CGC announcements. Check regularly for updates on clinical trials, retail partnerships, and operational developments that shape the company's position in the global cannabis industry.
Canopy Growth (Nasdaq: CGC) has established a new US$200 million at-the-market (ATM) equity program to strengthen its financial position. The program allows the company to issue and sell common shares through concurrent public offerings in the United States and Canada, with Canadian sales limited to US$50 million.
The ATM program will be effective until June 5, 2027, or until the total offering amount is reached. Shares will be sold at prevailing market prices through BMO Nesbitt Burns Inc. (Canada) and BMO Capital Markets Corp. (USA). The proceeds will be used for business investments, potential acquisitions, working capital, and possible debt repayment.
Canopy USA (NASDAQ:CGC) has appointed Eric Ruhle as Vice President of Brand Sales to oversee sales strategy across its cannabis brand portfolio. Ruhle brings over 11 years of cannabis industry experience, most recently serving as Senior Regional Sales Manager at Kiva Sales & Services.
In his new role, Ruhle will focus on expanding retail presence, strengthening distributor partnerships, and launching go-to-market initiatives to drive revenue growth. His previous leadership positions at Marley Natural, dosist, and Final Bell demonstrate his expertise in scaling multi-brand portfolios and developing retail partnerships.
Canopy USA (NASDAQ:CGC) has announced the appointment of a new executive leadership team to drive its expansion across the U.S. cannabis market. The key appointments include Casey Rash as Chief Financial Officer, Rebecca Kirk as Chief Operating Officer, and Kelly Flores as Chief Business Development Officer.
Under the leadership of President Brooks Jorgensen, the team will focus on portfolio growth, operational improvements, and market expansion. The company's platform combines assets from Acreage, Jetty, and Wana, aiming to deliver consistent quality products and trusted brands nationwide.
Canopy Growth (NASDAQ:CGC) has announced the mailing of proxy materials for its upcoming 2025 Annual General and Special Meeting, scheduled for September 26, 2025, at 1:00 PM ET. The virtual meeting requires a quorum of 33 1/3% of outstanding shares to proceed.
Shareholders will vote on four key items: director elections, auditor reappointment, a proposed reverse stock split, and an advisory vote on executive compensation. The board recommends voting FOR all resolutions. Shareholders of record as of August 1, 2025, can vote online at proxyvote.com, by phone, or through various other platforms depending on their broker.
Canopy Growth (Nasdaq: CGC) reported strong Q1 FY2026 financial results, with total revenue increasing 9% year-over-year to $72.1 million. The company's Canada adult-use cannabis revenue surged 43% to $27 million, driven by increased distribution and strong demand for new products, particularly Claybourne infused pre-roll joints.
The company achieved $17 million of its planned $20 million annualized savings target since March 2025, with SG&A expenses down 21% year-over-year. However, gross margin decreased to 25% from 35% in Q1 FY2025, primarily due to lower Storz & Bickel sales and product mix shifts. The company reported a net loss of $41.5 million, showing a 68% improvement from the previous year.
Additionally, Canopy Growth announced the appointment of Shan Atkins to its Board of Directors, bringing extensive retail strategy and operations experience.
Canopy Growth (Nasdaq: CGC) has expanded its medical cannabis portfolio in Australia with the launch of its 7ACRES brand. The company introduced two high-THC sativa strains: Ultra Jack and Jack Frost, available in 10g flower formats.
The expansion complements Canopy's existing Australian presence, which includes Tweed flower products and Spectrum Therapeutics oils. This launch leverages the company's improved global supply chain and Canadian production capabilities to strengthen its international medical platform.
Canopy Growth (Nasdaq: CGC) has appointed Miles Worne as Managing Director of European Markets, effective August 11, 2025. Worne, who previously served as President of Curaleaf International, brings over 20 years of experience in cannabis, healthcare, and consumer sectors.
The appointment aligns with Canopy Growth's strategic focus on European expansion, particularly in established medical markets. The company's European operations are supported by EU-GMP certified supply from its Kincardine facility, processing capabilities at St. Leon-Rot in Germany, and a global supply chain infrastructure.
Canopy Growth (NASDAQ:CGC) has announced a significant debt reduction initiative through an agreement with its lenders. The company will make three prepayments totaling US$50 million to reduce its Senior Secured Term Loan by March 31, 2026.
The prepayments will be made in three installments: US$25 million by July 31, 2025, US$10 million by December 31, 2025, and US$15 million by March 31, 2026. This debt reduction is expected to lower the company's annual cash interest expense by US$6.5 million.
Additionally, Canopy USA received consent to secure US$22 million in additional funding for Acreage Holdings and its subsidiaries.
Canopy Growth (NASDAQ:CGC) has scheduled its first quarter fiscal 2026 financial results release for August 8, 2025, before market open. The company will host an audio webcast at 10:00 AM ET on the same day, featuring CEO Luc Mongeau and Interim CFO Tom Stewart.
The webcast will be available live and accessible for replay until November 6, 2025 at 11:59 PM ET through the company's online portal.
Canopy Growth (Nasdaq: CGC) has launched Deep Space Infused pre-rolls, combining high-quality flower with liquid diamonds and THCA diamonds to achieve THC levels above 60%. The product comes in a 3x0.5g format with two flavors: Milky Way Melon Infused and Big Bang Berry Infused.
The launch is part of Canopy's strategy to expand in the fast-growing pre-roll category, particularly in the infused segment. This follows recent Deep Space beverage and gummy innovations, building on the success of Claybourne's Frosted Flyers launched in November 2024.
The products are now available at licensed retailers across select regions in Canada, including the Spectrum Therapeutics online store for medical consumers.
FAQ
What is the current stock price of Canopy Growth (CGC)?
What is the market cap of Canopy Growth (CGC)?
